Roche Diagnostics has announced extended survival for people with aggressive form of breast cancer through its trastuzumab emtansine (T-DM1).
The company revealed individuals with HER-2 positive metastatic breast cancer that previously went untreated survived considerably longer with T-DM1 treatment compared to a lapatinib and Xeloda combination.
Findings from the Phase III EMILIA study revealed death risk fell by 32 percent for patients receiving T-DM1 treatment rather than the other care option.
It was shown that those with T-DM1 lived 5.8 months longer than those who received a mix of lapatinib and Xeloda.
Hal Barron, chief medical officer and head of global product development at Roche - which has more than 80,000 employees around the world - said: "We are extremely pleased that the new data from the EMILIA study showed people receiving trastuzumab emtansine survived longer than those who received the standard of care."
He added the company is continuing to work alongside regulatory authorities in a bid to bring even more innovation to this field of medicine.See all the latest jobs in Medical Devices